U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C3H7NO3
Molecular Weight 105.0926
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERINE

SMILES

N[C@@H](CO)C(O)=O

InChI

InChIKey=MTCFGRXMJLQNBG-REOHCLBHSA-N
InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m0/s1

HIDE SMILES / InChI

Molecular Formula C3H7NO3
Molecular Weight 105.0926
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22045570 | https://www.ncbi.nlm.nih.gov/pubmed/27589995 | https://clinicaltrials.gov/ct2/show/NCT03062449

L-serineThe is a non-essential amino acid. L-serine and the products of its metabolism have been recognized not only to be essential for cell proliferation, but also to be necessary for specific functions in the central nervous system. The findings of altered levels of serine and glycine in patients with psychiatric disorders and the severe neurological abnormalities in patients with defects of L-serine synthesis underscore the importance of L-serine in brain development and function. L-serine supplementation is in trials for the treatment of several CNS diseases such as Alzheimer's disease, Hereditary sensory and autonomic neuropathy type 1 and Amyotrophic Lateral Sclerosis

CNS Activity

Curator's Comment: The de novo synthesis of the amino acid L-serine plays an essential role in the development and functioning of the central nervous system (CNS). L-serine displays many metabolic functions during different developmental stages; among its functions providing precursors for amino acids, protein synthesis, nucleotide synthesis, neurotransmitter synthesis and L-serine derived lipids. Patients with congenital defects in the L-serine synthesizing enzymes present with severe neurological abnormalities and underscore the importance of this synthetic pathway.

Originator

Sources: Cramer, E. (1865) Ueber die bestandtheile der seide. J. Prakt. Chem. 96, 76–98
Curator's Comment: refernce retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12534373

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FREAMINE III 10%

Approved Use

Parenteral nutrition with 8.5% FreAmine® III (Amino Acid Injection) with Electrolytes is indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric patients, where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance

Launch Date

1971
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
The ddcA gene from Streptomyces fradiae encodes an extracellular beta-lactamase with penicillinase and cephalosporinase activities.
2001-11-30
Nucleocytoplasmic shuttling of heterodimeric splicing factor U2AF.
2001-04-20
Differential regulation of the uridine nucleotide-activated P2Y4 and P2Y6 receptors. SER-333 and SER-334 in the carboxyl terminus are involved in agonist-dependent phosphorylation desensitization and internalization of the P2Y4 receptor.
2001-04-13
alpha 1-Proteinase inhibitor, alpha 1-antichymotrypsin, and alpha 2-macroglobulin are the antiapoptotic factors of vascular smooth muscle cells.
2001-04-13
Mutational and X-ray crystallographic analysis of the interaction of dihomo-gamma -linolenic acid with prostaglandin endoperoxide H synthases.
2001-03-30
Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control.
2001-03-30
Phosphorylation of tau is regulated by PKN.
2001-03-30
Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.
2001-03-23
Polymerization of plasminogen activator inhibitor-1.
2001-03-23
Identification of the E2A gene products as regulatory targets of the G1 cyclin-dependent kinases.
2001-03-16
Structure and expression of the murine phosphatidylserine synthase-1 gene.
2001-03-16
The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase.
2001-03-09
Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition.
2001-03-09
Characterization of phosphatidylserine transport to the locus of phosphatidylserine decarboxylase 2 in permeabilized yeast.
2001-03-09
Substitution of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signaling.
2001-03-09
Calpain mutants with increased Ca2+ sensitivity and implications for the role of the C(2)-like domain.
2001-03-09
Thermal denaturation of the Na,K-ATPase provides evidence for alpha-alpha oligomeric interaction and gamma subunit association with the C-terminal domain.
2001-03-09
Overexpression and characterization of carboxyl-terminal processing protease for precursor D1 protein: regulation of enzyme-substrate interaction by molecular environments.
2001-03-09
The fission yeast TOR homolog, tor1+, is required for the response to starvation and other stresses via a conserved serine.
2001-03-09
The basis of prostaglandin synthesis in coral: molecular cloning and expression of a cyclooxygenase from the Arctic soft coral Gersemia fruticosa.
2001-03-09
The two major plant plasma membrane H+-ATPases display different regulatory properties.
2001-03-09
Porphyromonas gingivalis DPP-7 represents a novel type of dipeptidylpeptidase.
2001-03-02
Residue Met(156) contributes to the labile enzyme conformation of coagulation factor VIIa.
2001-03-02
Elimination of phosphorylation sites of Semliki Forest virus replicase protein nsP3.
2001-02-23
Interaction of paxillin with p21-activated Kinase (PAK). Association of paxillin alpha with the kinase-inactive and the Cdc42-activated forms of PAK3.
2001-02-23
Probing the mechanism of inactivation of human pyruvate dehydrogenase by phosphorylation of three sites.
2001-02-23
Phosphorylation-induced change of the oligomerization state of alpha B-crystallin.
2001-02-16
The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner.
2001-02-16
Phosphatidylinositol 4-phosphate 5-kinase type I is regulated through phosphorylation response by extracellular stimuli.
2001-02-16
First isolation of human UDP-D-xylose: proteoglycan core protein beta-D-xylosyltransferase secreted from cultured JAR choriocarcinoma cells.
2001-02-16
Heterologous activation of protein kinase C stimulates phosphorylation of delta-opioid receptor at serine 344, resulting in beta-arrestin- and clathrin-mediated receptor internalization.
2001-02-16
Phosphorylation of the pro-apoptotic protein BIK: mapping of phosphorylation sites and effect on apoptosis.
2001-02-16
Myosin I phosphorylation is increased by chemotactic stimulation.
2001-02-16
The protease inhibitor, MG132, blocks maturation of the amyloid precursor protein Swedish mutant preventing cleavage by beta-Secretase.
2001-02-09
alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases.
2001-02-09
Chloroplast RNA editing required for functional acetyl-CoA carboxylase in plants.
2001-02-09
Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation. Protein sorting at the level of the endoplasmic reticulum.
2001-02-09
Model systems to assess the destructive potential of human neutrophils and monocyte-derived macrophages during the acute and chronic phases of inflammation.
2001-02
Alterations in the chain dynamics of insoluble elastin upon proteolysis by serine elastases.
2001-02
Characterization of the stromal protease(s) degrading the cross-linked products of the D1 protein generated by photoinhibition of photosystem II.
2001-01-19
Metabolism of glucagon by dipeptidyl peptidase IV (CD26).
2001-01-12
Exaggerated responses to chronic nociceptive stimuli and enhancement of N-methyl-D-aspartate receptor-mediated synaptic transmission in mutant mice lacking D-amino-acid oxidase.
2001-01-05
Folding pathway mediated by an intramolecular chaperone: the structural and functional characterization of the aqualysin I propeptide.
2001-01-05
Increasing the thermal stability of euphauserase. A cold-active and multifunctional serine protease from Antarctic krill.
2001-01
Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis.
2001-01
Utilizing the peptidyl-prolyl cis-trans isomerase pin1 as a probe of its phosphorylated target proteins. Examples of binding to nuclear proteins in a human kidney cell line and to tau in Alzheimer's diseased brain.
2001-01
In vitro degradation of the Neb-Trypsin modulating oostatic factor (Neb-TMOF) in gut luminal content and hemolymph of the grey fleshfly, Neobellieria bullata.
2001-01
Towards the molecular basis of sperm and egg interaction during mammalian fertilization.
2001
cDNA expression cloning and characterization of phosphorylation dependent protein interactors using the yeast tribrid system.
2001
Identification of receptor tyrosine kinase associating proteins using the yeast two-hybrid system.
2001
Patents

Sample Use Guides

Hereditary sensory and autonomic neuropathy type 1 (HSAN1) patients: 10-week oral l-serine 200 or 400 mg/kg body weight. Amyotrophic Lateral Sclerosis patients: twice-daily dose regimens (0.5, 2.5, 7.5, or 15 g/dose).
Route of Administration: Oral
Increasing L-serine medium concentrations (1-10 mM) substantially suppressed endogenous deoxysphinganine production in WT serine palmitoyltransferase SPTLC1 and hereditary sensory and autonomic neuropathy type 1 (HSAN1) mutant–expressing HEK293 cells
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:52:08 GMT 2025
Edited
by admin
on Mon Mar 31 17:52:08 GMT 2025
Record UNII
452VLY9402
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SERINE
EP   HSDB   II   INCI   INN   MART.   MI   USAN   USP   VANDF   WHO-DD  
INN   USAN   INCI  
Official Name English
L-SERINE
FCC   USP-RS  
Preferred Name English
SERINE [USP MONOGRAPH]
Common Name English
SERINE [MART.]
Common Name English
SERINE [HSDB]
Common Name English
serine [INN]
Common Name English
SERINE [EP MONOGRAPH]
Common Name English
SERINE [MI]
Common Name English
SERINE [II]
Common Name English
(2S)-2-AMINO-3-HYDROXY-PROPANOIC ACID
Common Name English
L-SERINE [JAN]
Common Name English
SERINE [VANDF]
Common Name English
SERINE [USAN]
Common Name English
NSC-118365
Code English
L-(-)-SERINE
Common Name English
L-SERINE [USP-RS]
Common Name English
Serine [WHO-DD]
Common Name English
L-SERINE [FCC]
Common Name English
Classification Tree Code System Code
LOINC 2936-3
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 25523-2
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 22684-5
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 44403-4
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 47748-9
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 25979-6
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 32269-3
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 27223-7
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 47744-8
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 79601-1
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
NCI_THESAURUS C29596
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 2937-1
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 79645-8
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 15140-7
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 47747-1
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 22644-9
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 32270-1
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 2935-5
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 15136-5
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 47746-3
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 53395-0
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 13414-8
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 2938-9
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 47745-5
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 13808-1
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 17575-2
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
DSLD 1687 (Number of products:408)
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 47743-0
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 56642-2
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 30058-2
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 47742-2
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 20656-5
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 25980-4
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 22741-3
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 79618-5
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 2934-8
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
CFR 21 CFR 172.320
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
LOINC 26741-9
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
DSLD 168 (Number of products:1)
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
NCI_THESAURUS C68442
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
Code System Code Type Description
MERCK INDEX
m9869
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY Merck Index
CHEBI
33384
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
CAS
56-45-1
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
EPA CompTox
DTXSID60883230
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
RS_ITEM_NUM
1612506
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
HSDB
680
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
CHEBI
17115
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
CHEBI
17822
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
EVMPD
SUB10494MIG
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
RXCUI
9671
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY RxNorm
ECHA (EC/EINECS)
200-274-3
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
WIKIPEDIA
SERINE
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
DAILYMED
452VLY9402
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
INN
6170
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
PUBCHEM
5951
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
NSC
118365
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
MESH
D012694
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
ChEMBL
CHEMBL11298
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
EVMPD
SUB21990
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
DRUG BANK
DB00133
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
SMS_ID
100000084137
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
DRUG CENTRAL
4127
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
FDA UNII
452VLY9402
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
NCI_THESAURUS
C29613
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
CHEBI
29999
Created by admin on Mon Mar 31 17:52:08 GMT 2025 , Edited by admin on Mon Mar 31 17:52:08 GMT 2025
PRIMARY
Related Record Type Details
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY